EMR 100070-001: Phase I study of MSB0010718C in solid tumors

• Research type

  Research Study

• Full title

  A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of avelumab (MSB0010718C) in subjects with metastatic or locally advanced solid tumors and expansion to selected indications.

• IRAS ID

  137236

• Contact name

  Rebecca Roylance

• Contact email

  r.roylance@ucl.ac.uk

• Sponsor organisation

  Merck KGaA

• Eudract number

  2013-002834-19

• Clinicaltrials.gov Identifier

  NCT01772004

• REC name

  London - Central Research Ethics Committee

• REC reference

  13/LO/1766

• Date of REC Opinion

  11 Dec 2013

• REC opinion

  Favourable Opinion